Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model¹

详细信息    查看全文

• 作者：Nobuyuki Tanaka ; M.D. ; Ph.D.^a ; ^e ; ^{urotanaka@gmail.com} ; Ryuichi Mizuno ; M.D. ; Ph.D.^a ; ^{mizunor@z7.keio.jp} ; Yota Yasumizu ; M.D.^b ; Keiichi Ito ; M.D. ; Ph.D.^c ; Suguru Shirotake ; M.D. ; Ph.D.^b ; Ayako Masunaga ; M.D.^c ; Yujiro Ito ; M.D.^d ; Yasumasa Miyazaki ; M.D.^a ; Masayuki Hagiwara ; M.D.^g ; Kent Kanao ; M.D. ; Ph.D.ⁱ ; Shuji Mikami ; M.D. ; Ph.D.^h ; Ken Nakagawa ; M.D. ; Ph.D.^g ; Tetsuo Momma ; M.D. ; Ph.D.^f ; Takeshi Masuda ; M.D.^e ; Tomohiko Asano ; M.D. ; Ph.D.^c ; Masafumi Oyama ; M.D. ; Ph.D.^b ; Mototsugu Oya ; M.D. ; Ph.D.^a
• 关键词：Renal cell carcinoma ; Targeted therapy ; Metastasis ; Outcome ; Prognosis ; Neutrophil ; NLR
• 刊名：Urologic Oncology: Seminars and Original Investigations
• 出版年：2017
• 出版时间：February 2017
• 年：2017
• 卷：35
• 期：2
• 页码：39.e19-39.e28
• 全文大小：919 K
• 卷排序：35

文摘

Pretreatment NLR elevation is associated with poor OS of mRCC after targeted therapy. Normalization of NLR levels after treatment may be prognostic in mRCC. The addition of NLR significantly improves the predictive accuracy of the IMDC risk model.